Application of a genetic signature of late GU toxicity in SCIMITAR, a Post-op SBRT trial

Predictors of genitourinary toxicity after post-prostatectomy radiotherapy remain elusive. A previously defined germline DNA signature (PROSTOX) has shown predictive ability for late grade >= 2 GU toxicity after intact prostate stereotactic body radiotherapy. We explore whether PROSTOX would predict toxicity among patients receiving post-prostatectomy SBRT on a phase II clinical trial.

Automated summary

The predictors of genitourinary toxicity after post-prostatectomy radiotherapy are still unknown. A previously defined germline DNA signature (PROSTOX) has shown to be able to predict late grade>=2 genitourinary toxicity after intact prostate stereotactic body radiotherapy. We investigate whether PROSTOX can predict toxicity among patients receiving post-prostatectomy SBRT in a phase II clinical trial.